Autolus Therapeutics Plc (AUTL)
1.81
+0.04
(+2.26%)
USD |
NASDAQ |
Oct 09, 16:00
1.81
0.00 (0.00%)
After-Hours: 20:00
Autolus Therapeutics Cash from Operations (Quarterly) : -25.16M for June 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -25.16M |
| March 31, 2026 | -65.21M |
| December 31, 2025 | -67.21M |
| September 30, 2025 | -67.40M |
| June 30, 2025 | -74.06M |
| March 31, 2025 | -75.56M |
| December 31, 2024 | -37.93M |
| September 30, 2024 | -76.74M |
| June 30, 2024 | -51.08M |
| March 31, 2024 | -40.51M |
| December 31, 2023 | -24.83M |
| September 30, 2023 | -39.95M |
| June 30, 2023 | -38.27M |
| March 31, 2023 | -42.80M |
| December 31, 2022 | -14.50M |
| Date | Value |
|---|---|
| September 30, 2022 | -31.90M |
| June 30, 2022 | -30.81M |
| March 31, 2022 | -35.03M |
| December 31, 2021 | -9.158M |
| September 30, 2021 | -34.75M |
| June 30, 2021 | -36.61M |
| March 31, 2021 | -37.34M |
| December 31, 2020 | -27.73M |
| September 30, 2020 | -39.06M |
| June 30, 2020 | -26.93M |
| March 31, 2020 | -24.03M |
| December 31, 2019 | -33.27M |
| September 30, 2019 | -24.49M |
| June 30, 2019 | -17.21M |
| March 31, 2019 | -26.52M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Bicycle Therapeutics Plc | -49.69M |
| Biodexa Pharmaceuticals Plc | -- |
| argenx SE | -- |
| Mereo BioPharma Group Plc | -6.048M |
| Evaxion AS | -- |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | 68.03M |
| Cash from Financing (Quarterly) | -2.144M |
| Free Cash Flow | -240.12M |
| Free Cash Flow Per Share (Quarterly) | -0.098 |
| Free Cash Flow to Equity (Quarterly) | -24.77M |
| Free Cash Flow to Firm (Quarterly) | -26.08M |
| Free Cash Flow Yield | -49.85% |